Compare CVS Health Corp (CVS) vs Figs Inc (FIGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Figs Inc — how do they compare? CVS Health Corp trades at $86.3 (market cap $112.49B), while Figs Inc trades at $14.96 (market cap $2.34B). The key difference: CVS Health Corp is far larger — about 48.1× Figs Inc's market cap, and CVS Health Corp pays a 3.02% dividend while Figs Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Figs Inc for 33 Days on average.
| CVS | FIGS | |
|---|---|---|
Market Cap | $112.49B | $2.34B |
Volume | 8,467,392 | 6,865,366 |
Sector | Health | Consumer Cyclical |
52-Week High | $110.60 | $17.12 |
52-Week Low | $70.08 | $6.90 |
Typical Hold Time | 83 Days | 33 Days |
Enterprise Value | $174.83B | $2.10B |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
FIGS stock trades at $14.98, up 6.24% today, with strong technical momentum and bullish moving averages. The company shows accelerating revenue growth, with 2025 revenue reaching $631.10M and net income of $34.25M. Recent earnings beats and raised 2026 guidance signal operational strength, though valuation multiples remain elevated with a P/E of 42.61. International expansion continues to drive growth, with Q2 international sales surging 67%.
The outlook remains positive with analyst consensus pointing to 26.4% upside potential to $18.00 target. Strong fundamentals and momentum are balanced by rich valuation requiring continued execution. Key risks include premium pricing pressure and competitive threats in healthcare apparel. Wall Street sentiment leans bullish with 60% buy ratings among 15 analysts covering the stock.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →
